Skip to content
eventVerified

WHO listed Comirnaty under Emergency Use Listing

On 31 December 2020, WHO listed the Pfizer/BioNTech Comirnaty mRNA vaccine for emergency use, the first COVID-19 vaccine to receive WHO emergency validation. In the causal graph this event weakens COVID-19 pandemic, a driver that weakens Life expectancy at birth — an improving welfare path.

Read the full account

On 31 December 2020, WHO listed the Pfizer/BioNTech Comirnaty mRNA vaccine for emergency use, the first COVID-19 vaccine to receive WHO emergency validation. The listing enabled countries and UN procurement channels to accelerate access. This is a response milestone that weakens the pandemic driver over time through protection against severe disease and death; it is not an assertion that transmission ended on the listing date.

Who was responsible

Contribution type and responsibility level for each recorded actor — not sole-author shorthand.

No public contributors are listed for this fact.

What changed

Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.

    1. FactWHO listed Comirnaty under Emergency Use Listing
    2. weakensDriverCOVID-19 pandemic
    3. weakensIndicators (3)Life expectancy at birth
    Improving path

    impact weight 0.4 · verified

    Direction reflects a response mechanism; no unique global coefficient is invented. [impact_weight null in pack → provisional 0.4 stored only because fact_driver_impacts.impact_weight is NOT NULL; not a sourced magnitude]

    • Life expectancy at birth

      via COVID-19 pandemic

      Better

      Weakens · Relationship strength 0.3 (weight 0.4 × strength 0.75)

      Observed

      80 Years · 2.3 below the normal line (2023)

      Worse than normal

      6 readings, 2018–2023: rose from 79.5 Years to 80 Years.

      Above normal = better

    • Under-five mortality rate (global)

      via COVID-19 pandemic

      Better

      Strengthens · Relationship strength 0.28 (weight 0.4 × strength 0.7)

      Observed

      37.4 deaths per 1,000 live births · 12.4 above the normal line (2024)

      Worse than normal

      7 readings, 2018–2024: fell from 40 deaths per 1,000 live births to 37.4 deaths per 1,000 live births.

      Above normal = worse

    • First-dose measles vaccination coverage (global, MCV1)

      via COVID-19 pandemic

      Better

      Weakens · Relationship strength 0.26 (weight 0.4 × strength 0.65)

      Observed

      84% of one-year-olds · 11 below the normal line (2024)

      Worse than normal

      7 readings, 2018–2024: fell from 86.4% of one-year-olds to 84% of one-year-olds.

      Above normal = better

    1. FactWHO listed Comirnaty under Emergency Use Listing
    2. strengthensDrivermRNA-Platform Development

    provisional weight · verified

Causal path

How this event connects to drivers and indicators in the graph.

  1. FactWHO listed Comirnaty under Emergency Use Listing
  2. weakensDrivers (2)COVID-19 pandemic
  3. weakensIndicatorLife expectancy at birth

Cite this page

Factrail. (2026). WHO listed Comirnaty under Emergency Use Listing. Factrail. https://factrail.ai/facts/who-eul-comirnaty-covid-mrna-vaccine-2020

https://factrail.ai/facts/who-eul-comirnaty-covid-mrna-vaccine-2020

Accessed 16 October 2026.

By the Factrail desk · Method: how we source and score · Last reviewed

Dispute this factNamed here, or represent someone who is? Request a right of reply.